SPOP mutations in veterans with metastatic castration-resistant prostate cancer (mCRPC) and the association with race and response to an androgen receptor pathway inhibitor (ARPI). This is an ASCO ...
(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics ...
The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted ...
MedPage Today on MSN
Good Cancer Control, Survival With SBRT for Limited Metastatic/Progressive Disease
Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers.
Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...
Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...
A subset of metastatic prostate cancers progress on hormonal therapy to a non–androgen-receptor-dependent phenotype characterized by tumor suppressor loss, neuroendocrine features, and aggressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback